Go online to PeerView.com/JGU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, a panel of leading experts discuss recent developments in prostate cancer and offer thoughts on how to integrate a range of novel therapeutics and optimally navigate patient care for those with prostate cancer. Using case vignettes, the experts address real-world applications of the latest research, including selection and sequencing of approved therapies and which patients may benefit from enrollment in clinical trials. Upon completion of this activity, participants should be better able to: Examine the recent safety and efficacy data of emerging and available agents for metastatic castration-sensitive and nonmetastatic castration-resistant prostate cancer, Review the latest evidence and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, taxanes, and bone-directed therapies, alone or in combination for nonmetastatic and metastatic prostate cancers, Examine the role of genetic testing to better guide treatment decision-making throughout the prostate cancer continuum, Summarize emerging evidence of monotherapy and combination strategies, including PARP and immune checkpoint inhibitor therapies, for the management of prostate cancer, Plan evidence-based, personalized treatment algorithms, including the consideration of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.